US 4444879A
· Foster et al.
· 1984
[cited by applicant]
US 4863873A
· Matson
· 1989
[cited by applicant]
US 5366140A
· Koskenmaki et al.
· 1994
[cited by applicant]
US 5498545A
· Vestal
· 1996
[cited by applicant]
US 5900481A
· Lough et al.
· 1999
[cited by applicant]
US 5928952A
· Hutchins et al.
· 1999
[cited by applicant]
US 5952653A
· Covey et al.
· 1999
[cited by applicant]
US 6291183B1
· Pirrung et al.
· 2001
[cited by applicant]
US 6327410B1
· Walt et al.
· 2001
[cited by applicant]
US 6329209B1
· Wagner et al.
· 2001
[cited by applicant]
US 6361944B1
· Mirkin et al.
· 2002
[cited by applicant]
US 6413780B1
· Bach et al.
· 2002
[cited by applicant]
US 6514416B1
· Harradine et al.
· 2003
[cited by applicant]
US 6649419B1
· Anderson
· 2003
[cited by applicant]
US 6730517B1
· Koster et al.
· 2004
[cited by applicant]
US 6759010B2
· Lewis et al.
· 2004
[cited by applicant]
US 6942968B1
· Dickinson et al.
· 2005
[cited by applicant]
US 6969615B2
· Knezevic et al.
· 2005
[cited by applicant]
US 7348184B2
· Rich et al.
· 2008
[cited by applicant]
US 7375234B2
· Sharpless et al.
· 2008
[cited by applicant]
US 7442921B2
· Franzen
· 2008
[cited by applicant]
US 7754861B2
· Boschetti et al.
· 2010
[cited by applicant]
US 7960184B2
· Morozov et al.
· 2011
[cited by applicant]
US 8021891B2
· Rotello et al.
· 2011
[cited by applicant]
US 8268264B2
· Lenz
· 2012
[cited by applicant]
US 8304187B2
· Fernando
· 2012
[cited by applicant]
US 8357537B2
· Blecka et al.
· 2013
[cited by applicant]
US 8586306B2
· Fernando
· 2013
[cited by applicant]
US 8795960B2
· Seul et al.
· 2014
[cited by applicant]
US 8906608B2
· Boschetti et al.
· 2014
[cited by applicant]
US 9005994B2
· Huo
· 2015
[cited by applicant]
US 9234895B2
· Hood et al.
· 2016
[cited by applicant]
US 9549901B2
· Shi et al.
· 2017
[cited by applicant]
US 9657227B2
· Fernando
· 2017
[cited by applicant]
US 9689039B2
· Wong et al.
· 2017
[cited by applicant]
US 9758811B2
· Brown et al.
· 2017
[cited by applicant]
US 9926590B2
· Fernando
· 2018
[cited by applicant]
US 9945994B2
· Hebrink et al.
· 2018
[cited by applicant]
US 20020009394A1
· Koster et al.
· 2002
[cited by applicant]
US 20020094533A1
· Hess et al.
· 2002
[cited by applicant]
US 20020102578A1
· Dickinson et al.
· 2002
[cited by applicant]
US 20020127727A1
· Bach et al.
· 2002
[cited by applicant]
US 20040106131A1
· Roy et al.
· 2004
[cited by applicant]
US 20040147040A1
· Bluggel et al.
· 2004
[cited by applicant]
US 20040153249A1
· Zhang et al.
· 2004
[cited by applicant]
US 20050053999A1
· Gough et al.
· 2005
[cited by applicant]
US 20050148101A1
· Bamdad et al.
· 2005
[cited by applicant]
US 20070072250A1
· Kim et al.
· 2007
[cited by applicant]
US 20070178504A1
· Colpitts et al.
· 2007
[cited by applicant]
US 20070224644A1
· Liotta et al.
· 2007
[cited by applicant]
US 20090253181A1
· Vangbo et al.
· 2009
[cited by applicant]
US 20100267108A1
· Jordaan et al.
· 2010
[cited by applicant]
US 20100291224A1
· Tong et al.
· 2010
[cited by applicant]
US 20110111978A1
· Boschetti et al.
· 2011
[cited by applicant]
US 20110306514A1
· Hewitt et al.
· 2011
[cited by applicant]
US 20120043208A1
· Jin et al.
· 2012
[cited by applicant]
US 20120046184A1
· Dawson et al.
· 2012
[cited by applicant]
US 20120171694A1
· Mansfield et al.
· 2012
[cited by applicant]
US 20130058923A1
· Huo
· 2013
[cited by applicant]
US 20130084561A1
· Coull et al.
· 2013
[cited by applicant]
US 20160327554A1
· Hung et al.
· 2016
[cited by applicant]
US 20170007725A1
· Khoury et al.
· 2017
[cited by applicant]
US 20170074869A1
· Krijgsveld et al.
· 2017
[cited by applicant]
US 20170146527A1
· Kelly et al.
· 2017
[cited by applicant]
US 20180136231A1
· Borrebaeck et al.
· 2018
[cited by applicant]
US 20180361000A1
· Weissleder et al.
· 2018
[cited by applicant]
US 20190117799A1
· Xu et al.
· 2019
[cited by applicant]
US 20200085758A1
· Farokhzad et al.
· 2020
[cited by applicant]
US 20200138728A1
· Farokhzad et al.
· 2020
[cited by applicant]
US 20210072255A1
· Farokhzad et al.
· 2021
[cited by applicant]
US 20210098083A1
· Ma et al.
· 2021
[cited by applicant]
US 20210215709A1
· Zhao et al.
· 2021
[cited by applicant]
US 20210293801A1
· Farokhzad et al.
· 2021
[cited by applicant]
US 20210311064A1
· Farokhzad et al.
· 2021
[cited by applicant]
US 20220260559A1
· Blume et al.
· 2022
[cited by applicant]
US 20220334123A1
· Farokhzad et al.
· 2022
[cited by applicant]
US 20220365096A1
· Farokhzad et al.
· 2022
[cited by applicant]
US 20230076840A1
· Farokhzad et al.
· 2023
[cited by applicant]
US 20230160882A1
· Siddiqui et al.
· 2023
[cited by applicant]
US 20230212647A1
· Farokhzad et al.
· 2023
[cited by applicant]
US 20230253113A1
· Guturu et al.
· 2023
[cited by applicant]
US 20230324401A1
· Farokhzad et al.
· 2023
[cited by applicant]
US 20240044885A1
· Farokhzad et al.
· 2024
[cited by applicant]
CN 1811406A
· 2006
[cited by applicant]
CN 1997284A
· 2007
[cited by applicant]
CN 102798658A
· 2012
[cited by applicant]
CN 103703143A
· 2014
[cited by applicant]
CN 105126736A
· 2015
[cited by applicant]
CN 105771942A
· 2016
[cited by applicant]
CN 106268707A
· 2017
[cited by applicant]
CN 106432644A
· 2017
[cited by applicant]
CN 107991277A
· 2018
[cited by applicant]
DE 202017107858U1
· 2018
[cited by applicant]
DE 202017007363U1
· 2021
[cited by applicant]
EP 1308520A2
· 2003
[cited by applicant]
EP 2209893A1
· 2010
[cited by applicant]
EP 3510402A1
· 2019
[cited by applicant]
EP 3548652A1
· 2019
[cited by applicant]
EP 3554681A1
· 2019
[cited by applicant]
EP 3877400A2
· 2021
[cited by applicant]
EP 3554681B1
· 2022
[cited by applicant]
EP 4056263A1
· 2022
[cited by applicant]
JP H06500358A
· 1994
[cited by applicant]
JP 2003517998A
· 2003
[cited by applicant]
JP 2009509132A
· 2009
[cited by applicant]
JP 2009524828A
· 2009
[cited by applicant]
WO WO0244327A2
· 2002
[cited by applicant]
WO WO2007010252A1
· 2007
[cited by applicant]
WO WO2007089731A2
· 2007
[cited by applicant]
WO WO2007091077A1
· 2007
[cited by applicant]
WO WO2009047526A1
· 2009
[cited by applicant]
WO WO2010097785A1
· 2010
[cited by applicant]
WO WO2010148365A2
· 2010
[cited by applicant]
WO WO2010148365A3
· 2011
[cited by applicant]
WO WO2011088128A2
· 2011
[cited by applicant]
WO WO2012006385A2
· 2012
[cited by applicant]
WO WO2012068226A3
· 2012
[cited by applicant]
WO WO2012106385A2
· 2012
[cited by applicant]
WO WO2012170711A1
· 2012
[cited by applicant]
WO WO2013022995A2
· 2013
[cited by applicant]
WO WO2015118152A1
· 2015
[cited by applicant]
WO WO2018046542A1
· 2018
[cited by applicant]
WO WO2018112460A1
· 2018
[cited by applicant]
WO WO2019083856A1
· 2019
[cited by applicant]
WO WO2019133892A1
· 2019
[cited by applicant]
WO WO2020096631A2
· 2020
[cited by applicant]
WO WO2020198209A1
· 2020
[cited by applicant]
WO WO2021026172A1
· 2021
[cited by applicant]
WO WO2021087407A1
· 2021
[cited by applicant]
WO WO2022020272A1
· 2022
[cited by applicant]
Sigdel, T.K. et al. Optimization for peptide sample preparation for urine peptidomics, Clinical Proteomics 2014, 11:7 (Year: 2014).
[cited by examiner]
Promega, Trypsin/Lys-C protease mix for enhanced protein mass spectrometry analysis, nature methods | Nov. 2013 (Year: 2013).
[cited by examiner]
Li, J. et al. Block copolymer conjugated Au-coated Fe3O4 nanoparticles as vectors for enhancing colloidal stability and cellular uptake, Journal of Nanobiotechnology, (2017) 15:56 (Year: 2017).
[cited by examiner]
Aebersold, R., et al. How many human proteoforms are there? Nat Chem Biol 14, 206-214 (2018).
[cited by applicant]
Agasti et al. (Adv. Drug Deliv Rev. Mar. 8, 2010; 62(3):316-328) (Year: 2010).
[cited by applicant]
Aggarwal, P., Hall, J.B., Mcleland, C.B., Dobrovolskaia, M.A. & McNeil, S.E. Nanoparticle interaction with plasma proteins as it relates to particle biodistribution, biocompatibility and therapeutic efficacy. Advanced d…
[cited by applicant]
Ahn, J.-M. & Cho, J.-Y. Current serum lung cancer biomarkers. Journal of Molecular Biomarkers & Diagnosis 2013 (2013).
[cited by applicant]
Aksoy-Sagirli, P., et al. Paraoxonase-1 192/55 polymorphisms and the risk of lung cancer in a Turkish population. Anticancer Res 31, 2225-2229 (2011).
[cited by applicant]
Alavi et al.: Applying Automated Machine Learning to Accelerate Large-Scale Proteomics Data Analysis. Seer, Inc., Redwood City, CA; and Massachusetts General Hospital, Boston, MA. poster 1 page (2023).
[cited by applicant]
Alavi et al.: Applying Automated ML for Classification and Regression in Large-Scale Clinical Proteomics Datasets. Seer, Inc., Redwood City, CA, poster 1 page (2023).
[cited by applicant]
Alavi et al.: Challenges in Large Scale Proteomics Data Analysis: A Survey of Characterization and Correction Solutions for Batch Effects. Seer, Inc., Redwood City, CA, online video available at https://seer.bio/resourc…
[cited by applicant]
Alavi et al.: Challenges in Large Scale Proteomics Data Analysis: A Survey of Characterization and Correction Solutions for Batch Effects. Seer, Inc., Redwood City, CA, poster 1 page (2022).
[cited by applicant]
Aldonza, M.B.D., et al. Paraoxonase-1 (PON1) induces metastatic potential and apoptosis escape via its antioxidative function in lung cancer cells. Oncotarget 8, 42817-42835 (2017).
[cited by applicant]
Alexopoulos, C., Blatsios, B. & Avgerinos, A. Serum lipids and lipoprotein disorders in cancer patients. Cancer 60, 3065-3070 (1987).
[cited by applicant]
Alexopoulos, C., Pournaras, S., Vaslamatzis, M., Avgerinos, A. & Raptis, S. Changes in serum lipids and lipoproteins in cancer patients during chemotherapy. Cancer chemotherapy and pharmacology 30, 412-416 (1992).
[cited by applicant]
Ali, et al. “Erlotinib-Conjugated Iron Oxide Nanoparticles as a Smart Cancer-Targeted Theranostic Probe for MRI.” Scientific reports vol. 6 36650. Nov. 11, 2016, doi:10.1038/srep36650.
[cited by applicant]
Altomare, et al., An in depth proteomic analysis based on ProteoMiner, affinity chromatography and nano-HPLC-MS/MS to explain the potential health benefits of bovine colostrum. Journal of pharmaceutical and biomedical a…
[cited by applicant]
Amici, A. et al. In vivo protein corona patterns of lipid nanoparticles. RSC Advances 7, 1137-1145 (2017).
[cited by applicant]
Andersen, J.D. et al. Identification of candidate biomarkers in ovarian cancer serum by depletion of highly abundant proteins and differential in-gel electrophoresis. Electrophoresis 31, 599-61O(2010).
[cited by applicant]
Anderson, et al. The Human Plasma Proteome, Molecular & Cellular Proteomics, 2002, 845-867.
[cited by applicant]
Anderson, L. Candidate-Based Proteomics in the Search for Biomarkers of Cardiovascular Disease. The Journal of physiology 2005, 563, 23-60.
[cited by applicant]
ANDERSON: The clinical plasma proteome: a survey of clinical assays for proteins in plasma and serum. Clin Chem 56(2):177-185 (2010).
[cited by applicant]
Andriole et al.: Mortality results from a randomized prostate-cancer screening trial. N Engl J Med. 360(13):1310-1319 doi:10.1056/NEJMoa0810696 (2009).
[cited by applicant]
Angel, T.E. et al. Mass spectrometry-based proteomics: existing capabilities and future directions. Chemical Society Reviews 41 , 3912-3928 (2012).
[cited by applicant]
Arvizo et al.: Identifying new therapeutic targets via modulation of protein corona formation by engineered nanoparticles. PLoS One 7(3):e33650, pp. 1-8 doi:10.1371/journal.pone.0033650 (2012).
[cited by applicant]
Ashby et al., Size and surface functionalization of iron oxide nanoparticles influence the composition and dynamic nature of their protein corona. ACS Appl. Mater. Interfaces 2014, 6, p. 15412-15419.
[cited by applicant]
Askim, J. R., Mahmoudi, M. & Suslick, K. S. Optical sensor arrays for chemical sensing: the optoelectronic nose. Chemical Society Reviews 42, 8649-8682 (2013).
[cited by applicant]
Auluck et al.: A Cloud-Scalable Software Suite for Large-Scale Proteogenomics Data Analysis and Visualization. Seer, Inc., Redwood City, CA, poster 1 page (2022).
[cited by applicant]
Bagalkot, V. et al. Quantum dot-aptamer conjugates for synchronous cancer imaging, therapy, and sensing of drug delivery based on bi-fluorescence resonance energy transfer. Nano letters 7, 3065-3070 (2007).
[cited by applicant]
Bakhtiary, Z. et al. Targeted superparamagnetic iron oxide nanoparticles for early detection of cancer: Possibilities and challenges. Nanomedicine: Nanotechnology, Biology and Medicine 12, 287-307 (2016).
[cited by applicant]
Bally, M., et al. “Liposome and lipid bilayer arrays towards biosensing applications.” Small 6.22 (2010): 2481-2497.
[cited by applicant]
Barkman et al.: Fabricated micro-nano devices for in vivo and in vitro biomedical applications. Wiley Interdiscip Rev Nanomed Nanobiotechnol 5(6):544-568 doi:10.1002/wnan.1236 (2013).
[cited by applicant]
Barran-Berdon, et al., Time Evolution of Nanoparticle-Protein corona in Human Plasma: Relevance for targeted drug delivery. Langmuir, 2013, 29, 6485-6494.
[cited by applicant]
Batth, Tanveer S et al. Protein Aggregation Capture on Microparticles Enables Multipurpose Proteomics Sample Preparation. Molecular & cellular proteomics : MCP vol. 18,5 (2019): 1027-1035. doi:10.1074/mcp.TIR118.001270.
[cited by applicant]
Baumann et al.: Standardized approach to proteome profiling of human serum based on magnetic bead separation and matrix-assisted laser desorption/ionization time-of-flight mass spectrometry. Clin Chem. 51(6):973-980 doi…
[cited by applicant]
Beck, H.C., Overgaard, M. & Rasmussen, L.M. Plasma proteomics to identify biomarkers-application to cardiovascular diseases. Translational Proteomics 7, 40-48 (2015).
[cited by applicant]
BEECKMANS: Chromatographic methods to study protein-protein interactions. Methods, Oct. 1999; 19(2):278-305.
[cited by applicant]
Benz et al.: Deep Plasma Proteomics at Scale with Proteograph™ Product Suite: A Performance Evaluation with Label-free and TMT Multiplexing Methods. Seer, Inc., Redwood City, CA; Sanford Burnham Prebys Medical Discovery…
[cited by applicant]
Beri, J., Rosenblatt, M.M., Strauss, E., Urh, M. & Bereman, M.S. Reagent for Evaluating Liquid Chromatography-Tandem Mass Spectrometry (LC-MS/MS) Performance in Bottom-Up Proteomic Experiments. Analytical chemistry 87, …
[cited by applicant]
Bertrand, N., et al. Mechanistic understanding of in vivo protein corona formation on polymeric nanoparticles and impact on pharmacokinetics. Nat Commun 8, 777 (2017).
[cited by applicant]
Bigbee et al.: Tumor Markers and Immunodiagnosis. Holland-Frei Cancer Medicine, 6th edition Hamilton (ON):BC Decker; Chapter 13, pp. 209-220 (2003).
[cited by applicant]
Bigdeli et al. “Exploring cellular interactions in liposomes using protein corona fingerprints and physicochemical properties”, ACS Nano, 10(3): 3723-3737 (2016).
[cited by applicant]
Bio-Rad, ProteoMinerTM Protein Enrichment Technology [Online] Available at: http://wolfson.huji.ac.il/purification/PDF/AlbuminRemoval/BIORAD_ProteoMiner.pdf. [Accessed Sep. 17, 2020].
[cited by applicant]
Bisker, et al. Protein-targeted corona phase molecular recognition. Nat Commun 7, 10241 (2016). https://doi. org/10.1038/ncomms10241.
[cited by applicant]
Bloom, D., Cafiero, E., Jane-Llopis, E., et al. The Global Economic Burden of Noncommunicable Diseases. Program on the Global Demography of Aging;2012.
[cited by applicant]
Bloomston, M. et al. Fibrinogen y overexpression in pancreatic cancer identified by large-scale proteomic analysis of serum samples. Cancer research 66, 2592-2599 (2006).
[cited by applicant]
Blume, et al., Analytical validation of the multi-nanoparticle proteograph platform for rapid and deep proteomic profiling. Seer, Inc. Apr. 2020. 1 Page.
[cited by applicant]
Blume, et al., Efficient and scalable profiling of a median of 1,779 plasma proteins in 288 subjects with multi-nanoparticle (NP) proteograph platform enables robust detection of early-stage non-small cell lung cancer (…
[cited by applicant]
Blume, et al., Proteograph, a novel multi-nanoparticle platform, enables rapid and deep proteomics profiling, significantly improving coverage, throughput, and scalability versus existing methods. Seer, Inc. Jun. 2020. …
[cited by applicant]
Blume, et al. Rapid, deep and precise profiling of the plasma proteome with multi-nanoparticle protein corona. Nat Commun 11, 3662; 1-14 (2020). https://doi.org/10.1038/s41467-020-17033-7.
[cited by applicant]
Boca Scientific. Magtivio. MagSi-Tools 600, 1.0, 3.0 Product Description: pp. 1-2. Aug. 2018.
[cited by applicant]
Bodansky, O. & Mcinnes, G. F. Thermal coagulation of serum proteins in cancer, in the postoperative phase of surgery, and in the administration of adrenocorticotropic hormone. Cancer 3, 1-14 (1950).
[cited by applicant]
Bolstad, et al. A comparison of normalization methods for high density oligonucleotide array data based on variance and bias. Bioinformatics. Jan. 22, 2003;19(2):185-93.
[cited by applicant]
Boschetti, et al., Hexapeptide combinatorial ligand libraries: the march for the detection of the low-abundance proteome continues. BioTechniques, 2008; 44(5): 663-665.
[cited by applicant]
Boschetti, et al., The ProteoMiner in the proteomic arena: a non-depleting tool for discovering low-abundance species. J Proteomics, Aug. 2008. 71(3): 255-264.
[cited by applicant]
Brede et al., Applications of Nanoparticles in the Detection and Treatment of Kidney Diseases, Advances in Chronic kidney disease, vol. 20, Issue 6, Nov. 2013, pp. 454-465.
[cited by applicant]
Breiman, L. Random forests. Machine learning 45, 5-32 (2001).
[cited by applicant]
Brenner, et al., Gene Expression analysis by massively parallel signature sequencing (MPSS) on microbead arrays. Nature Biotechnology 18.6 (Jun. 2000): 630-634, doi:10.1038/76469.
[cited by applicant]
Burgess, et al., Nanoparticle-Based Method Identifies 2200 Proteins In A Cardiovascular Disease Study Covering Known Biomarkers Among Other Differentially Expressed Proteins. Seer, Inc. Nov. 2021. 1 Page.
[cited by applicant]
Buys et al.: Effect of screening on ovarian cancer mortality: the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Randomized Controlled Trial. JAMA 305(22):2295-2303 doi:10.1001/jama.2011.766 (2011).
[cited by applicant]
Byrne, J.C. et al. 2D-DIGE as a strategy to identify serum markers for the progression of prostate cancer. Journal of proteome research 8, 942-957 (2008).
[cited by applicant]
Calvo et al.: Clinical proteomics: from biomarker discovery and cell signaling profiles to individualized personal therapy. Biosci Rep. 25(1-2):107-125 doi:10.1007/s10540-005-2851-3 (2005).
[cited by applicant]
Campos, et al., In-Depth Plasma Proteomics Profiling With Nanoparticle-Based Proteograph Workflow: A Performance Evaluation Of Label-Free And TMT Multiplexing Approaches. Seer, Inc. Nov. 2021. 1 Page.
[cited by applicant]
Canchola, J.A., Tang, S., Hemyari, P., Paxinos, E. & Marins, E. Correct use of percent coefficient of variation (%CV) formula for log-transformed data. MOJPB 6, 316-317 (2017).
[cited by applicant]
Canovi et al.: Applications of surface plasmon resonance (SPR) for the characterization of nanoparticles developed for biomedical purposes. Sensors (Basel). 12(12):16420-16432 doi:10.3390/s121216420 (2012).
[cited by applicant]
Cao, Z., Tang, H.-Y., Wang, H., Liu, Q. & Speicher, D.W. Systematic comparison of fractionation methods for in-depth analysis of plasma proteomes. J Proteome Res 11, 3090-3100 (2012).
[cited by applicant]
Capriotti, A.L. et al. Label-free quantitative analysis for studying the interactions between nanoparticles and plasma proteins. Analytical and bioanalytical chemistry 405, 635-645 (2013).
[cited by applicant]
Capriotti et al.: Analytical methods for characterizing the nanoparticle-protein corona. Chromatographia 77(11-12):755-769 DOI:10.1007/s10337-014-2677-x (2014).
[cited by applicant]
Capriotti et al., Shotgun proteomic analytical approach for studying proteins adsorbed onto liposome surface, Anal Bioanal Chem, 2011, 401, 1195-1202.
[cited by applicant]
Caputo, et al. A protein corona-enabled blood test for early cancer detection. Nanoscale 9.1 (Jan. 7, 2017): 349-354.
[cited by applicant]
Caracciolo, et al., Evolution of the protein corona of lipid gene vectors as a function of plasma concentration. Langmuir, 2011, 27, 15048-15053.
[cited by applicant]
Caracciolo, G., Caputo, D., Pozzi, D., Colapicchioni, V. & Coppola, R. Size and charge of nanoparticles following incubation with human plasma of healthy and pancreatic cancer patients. Colloids and Surfaces B: Biointer…
[cited by applicant]
Caracciolo, G., et al. Lipid composition: a “key factor” for the rational manipulation of the liposome-protein corona by liposome design. RSC Adv 5, 5967-5975 (2015).
[cited by applicant]
Caracciolo, G., Farokhzad, O.C. & Mahmoudi, M. Biological Identity of Nanoparticles In Vivo: Clinical Implications of the Protein Corona. Trends in Biotechnology 35, 257-264 (2017).
[cited by applicant]
Carey, J. R. et al. Rapid identification of bacteria with a disposable colorimetric sensing array. Journal of the American Chemical Society 133, 7571-7576 (2011).
[cited by applicant]
Carter, A. M. Complement Activation: An Emerging Player in the Pathogenesis of Cardiovascular Disease. Scientifica 2012, 2012.
[cited by applicant]
Carter, H. B. et al. Early detection of prostate cancer: AUA Guideline. The Journal of urology 190, 419-426 (2013).
[cited by applicant]
Casals et al. Time evolution of the nanoparticle protein corona. ACS Nano. 4(7):3623-32. doi:10.1021/nn901372t (2010).
[cited by applicant]
Cedervall, T., et al. Understanding the nanoparticle-protein corona using methods to quantify exchange rates and affinities of proteins for nanoparticles. Proc Natl Acad Sci U S A 104, 2050-2055 (2007).
[cited by applicant]
Cerasoli, E. et al. MiS-MALDI: microgel-selected detection of protein biomarkers by MALDI-ToF mass spectrometry. Molecular Biosystems 6, 2214-2217 (2010).
[cited by applicant]
Chang, et al., Proteomic Profiling Of Prostate Cancer Plasma Specimens Using Proteograph And TIMS Technology. Seer, Inc. Nov. 2021. 1 Page.
[cited by applicant]
Chen et al.: Balancing deep proteome coverage with limited sample amounts using Seer's ProteographTM Product Suite. Application Note, Seer, Inc., Redwood City, CA, pp. 1-6 (2023).
[cited by applicant]
Chen et al.: Balancing deep proteome coverage with limited sample amounts using Seer's ProteographTM Product Suite. Seer, Inc., Redwood City, CA, poster 1 page (2023).
[cited by applicant]
Chintamaneni et al.: Biomarkers in Alzheimer's disease: a review. ISRN Pharmacol. 2012:984786:1-6 doi:10.5402/2012/984786 (2012).
[cited by applicant]
Choi, Y.-E., Kwak, J.-W. & Park, J. W. Nanotechnology for early cancer detection. Sensors 10, 428-455 (2010).
[cited by applicant]
Chung et al.: Novel serum protein biomarker panel revealed by mass spectrometry and its prognostic value in breast cancer. Breast Cancer Res. 16(3):R63:1-12 doi:10.1186/bcr3676 (2014).
[cited by applicant]
Clarke et al.: Characterization of renal allograft rejection by urinary proteomic analysis. Ann Surg. 237(5):660-664; discussion 664-665. doi:10.1097/01.SLA.0000064293.57770.42 (2003).
[cited by applicant]
Clemments, A. M. et al., Protein Adsorption From Biofluids on Silica Nanoparticles: Corona Analysis as a Function of Particle Diameter and Porosity, ACS Applied Materials & Interfaces 2015, 7, 21682-21689, with 5 pages …
[cited by applicant]
Colapicchioni, V. et al. Personalized liposome-protein corona in the blood of breast, gastric and pancreatic cancer patients. International Journal of Biochemistry and Cell Biology, 2015,75(11): 180-187.
[cited by applicant]
Consortium, E.P. Europe PMC: a full-text literature database for the life sciences and platform for innovation. Nucleic acids research, gku1061 (2014).
[cited by applicant]
Corbo, C. et al., Biomarker discovery by proteomics-based approaches for early detection and personalized medicine in colorectal cancer, Proteomics—Clinical Applications, 2017, 11, 5-6, paper 1600072, 19 pages.
[cited by applicant]
Corbo, C. et al. Unveiling the in Vivo Protein Corona of Circulating Leukocyte-like Carriers. ACS Nano (2017).
[cited by applicant]
Corbo, C., Molinaro, R., Parodi, A., Furman, N. E. T., Salvatore, F., Tasciotti, E. The Impact of Nanoparticle Protein Corona on Cytotoxicity, Immunotoxicity and Target Drug Delivery. Nanomedicine 2016, 11, 81-100.
[cited by applicant]
Corbo, C., Molinaro, R., Tabatabaei, M., Farokhzad, O.C. & Mahmoudi, M. Personalized protein corona on nanoparticles and its clinical implications. Biomater Sci 5, 378-387 (2017).
[cited by applicant]
Corbo, et al. Effects of the protein corona on liposome-liposome and liposome-cell interactions. Int J Nanomedicine. 2016; 11: 3049-3063. Published online Jul. 4, 2016. doi: 10.2147/IJN.S109059.
[cited by applicant]
Craig, R. & Beavis, R.C. Tandem: matching proteins with tandem mass spectra. Bioinformatics 20, 1466-1467 (2004).
[cited by applicant]
Cramer et al.: Ovarian cancer biomarker performance in prostate, lung, colorectal, and ovarian cancer screening trial specimens. Cancer Prev Res (Phila) 4(3):365-374 doi:10.1158/1940-6207.CAPR-10-0195 (2011).
[cited by applicant]
Croft, D. et al. The Reactome pathway knowledgebase. Nucleic acids research 42, D472-D477 (2013).
[cited by applicant]
Crutchfield, C.A., Thomas, S.N., Sokoll, L.J. & Chan, D.W. Advances in mass spectrometry-based clinical biomarker discovery. Clin Proteomics 13, 1 (2016).
[cited by applicant]
Cruz, J.A. & Wishart, D.S. Applications of machine learning in cancer prediction and prognosis. Cancer informatics 2, 59 (2006).
[cited by applicant]
Cuenca, A.G. et al. Emerging implications of nanotechnology on cancer diagnostics and therapeutics. Cancer 107, 459-466 (2006).
[cited by applicant]
Cuzick, J. et al. Prevention and early detection of prostate cancer. The Lancet Oncology 15, e484-e492, doi: 10.1016/ S1470-2045(2014)70211-6.
[cited by applicant]
Dai et al.: Combining proteograph technology with zeno swath dia acquisition enables the potential for deep, unbiased discovery of biomarkers in blood. PrognomiQ Inc., 1900 Alameda de las Pulgas, Suite 100, San Mateo, C…
[cited by applicant]
De Las Rivas, et al., Protein-Protein Interactions Essentials: Key Concepts to Building and Analyzing Interactome Networks. Plos computational biology, Jun. 2010; 6(6): e1000807, 1-8 Pages.
[cited by applicant]
Del Pilar et al.: Proteomic analysis of the bio-corona formed on the surface of (Au, Ag, Pt)-nanoparticles in human serum. Colloids and Surfaces B: Biointerfaces 177:141-148 doi:10.1016/j.colsurfb.2019.01.056 (2019).
[cited by applicant]
Del Pino, et al. Protein corona formation around nanoparticles—from the past to the future. Maler Horiz, 2014, 1, 301.
[cited by applicant]
Deng, Y., Qi, D., Deng, C., Zhang, X. & Zhao, D. Superparamagnetic high-magnetization microspheres with an Fe3O4@SiO2 core and perpendicularly aligned mesoporous SiO2 shell for removal of microcystins. J Am Chem Soc 130…
[cited by applicant]
Deng, Z.J., Liang, M., Monteiro, M., Toth, I. & Minchin, R.F. Nanoparticle-induced unfolding of fibrinogen promotes Mac-1 receptor activation and inflammation. Nature nanotechnology 6, 39-44 (2011).
[cited by applicant]
Deng, Z.J., Liang, M., Toth, I., Monteiro, M.J. & Minchin, R.F. Molecular interaction of poly (acrylic acid) gold nanoparticles with human fibrinogen. ACS nano 6, 8962-8969 (2012).
[cited by applicant]
Di Domenico, M. et al., Nanoparticle-biomolecular corona: A new approach for the early detection of non-small-cell lung cancer. Journal of Cellular Physiology 2019, 234, 9378-9386.
[cited by applicant]
Di Silvio, D. et al., Technical tip: high-resolution isolation of nanoparticle-protein corona complexes from physiological fluids, Nanoscale, 2015, 7, 11980-11990, with 7 pages of supplementary information.
[cited by applicant]
Digiacomo, L. et al., A protein corona sensor array detects breast and prostate cancers, Nanoscale 2020, 12, 16697-16704.
[cited by applicant]
Dobrovolskaia et al., Protein corona composition does not accurately predict hematocompatibility of colloidal gold nanoparticles, Nanomedicine: Nanotechnology, Biology, and Medicine, 2014, 10:1453-1463.
[cited by applicant]
Docter, D., et al. Quantitative profiling of the protein coronas that form around nanoparticles. Nat Protoc 9, 2030-2044 (2014).
[cited by applicant]
Docter, et al. The nanoparticle biomolecule corona: lessons learned-challenge accepted?. Chemical Society Reviews 44.17 (2015): 6094-6121.
[cited by applicant]
Donovan, et al., Deep, Rapid and Unbiased Plasma Proteomics with the Proteograph™ Product Suite Enables Proteogenomic Studies with Differential Analysis of Proteoforms. Seer, Inc. Sep. 2021. 5 Pages.
[cited by applicant]
Donovan et al.: Functionally distinct BMP1 isoforms show an opposite pattern of abundance in plasma from non-small cell lung cancer subjects and controls. PLoS One. 18(3):e0282821, pp. 1-11. doi:10.1371/journal.pone.028…
[cited by applicant]
Donovan et al.: Peptide-centric analyses of human plasma enable increased resolution of biological insights into non-small cell lung cancer relative to protein-centric analysis. Seer, Inc. Biorxiv 2022.01.07.475393, pp.…
[cited by applicant]
Donovan et al.: Proteoform inference using a proteogenomic approach in non-small cell lung cancer and healthy control plasma proteomes reveals disease-associated protein isoforms. Seer Inc., Redwood City, CA USA, poster…
[cited by applicant]
Dyna beads Products & Technology. ThennoFisher Scientific, Website accessed Dec. 15, 2021 at https://www.thermofisher.com/US/en/home/brands/product-brand/dynal/dynabeads-technology.html.
[cited by applicant]
Einav, S. et al. Early postoperative serum S10013 levels predict ongoing brain damage after meningioma surgery: a prospective observational study. Critical Care 10, 1 (2006).
[cited by applicant]
Elechalawar, C. K. et al, Analysing the nanoparticle-protein corona for potential molecular target identification, Journal of Controlled Release Jun. 10, 2020, 322, 122-136.
[cited by applicant]
Ellenberger et al.: Robust, high throughput and deep plasma proteomics workflow with engineered nanoparticle panels. Seer, Inc., Redwood City, CA, poster 1 page (2022).
[cited by applicant]
Ellenberger et al.: Robust in-depth label-free plasma proteomics with engineered nanoparticle panels: An evaluation of micro-pillar array cols. and FAIMS peptide separation. Seer, Inc., Redwood City, CA, poster 1 page (…
[cited by applicant]
Enroth, S., Hallmans, G., Grankvist, K. & Gyllensten, U. Effects of long-term storage time and original sampling month on biobank plasma protein concentrations. EBioMedicine 12, 309-314 (2016).
[cited by applicant]
Enten, A. et al., A Liquid-Handling Robot for Automated Attachment of Biomolecules to Microbeads, Journal of Laboratory Automation 2016, 21, 526-532.
[cited by applicant]
EP17881767.2 Extended European Search Report dated Jul. 22, 2020.
[cited by applicant]
Espina et al.: Use of proteomic analysis to monitor responses to biological therapies. Expert Opin Biol Ther. 4(1):83-93 doi:10.1517/14712598.4.1.83 (2004).
[cited by applicant]
Etzioni, R. et al. The case for early detection. Nature Reviews Cancer 3, 243-252 (2003).
[cited by applicant]
Everley, et al., Proteograph: Efficient and automated multi-nanoparticle platform for Deep, Unbiased Plasma protein profiling and protein-protein interaction biological insight. Seer, Inc. Mar. 2020.
[cited by applicant]
Faca, V. M. et al. A mouse to human search for plasma proteome changes associated with pancreatic tumor development. PLoS Med 5, e123 (2008).
[cited by applicant]
Farokhzad, 0. C. et al. Targeted nanoparticle-aptamer bioconjugates for cancer chemotherapy in vivo. Proceedings of the National Academy of Sciences 103, 6315-6320 (2006).
[cited by applicant]
Farrah, T., et al. A high-confidence human plasma proteome reference set with estimated concentrations in PeptideAtlas. Mol Cell Proteomics 10, M110 006353 (2011).
[cited by applicant]
Faunce et al.: Integrated research into the nanoparticle-protein corona: a new focus for safe, sustainable and equitable development of nanomedicines. Nanomedicine (Lond). 3(6):859-866 doi:10.2217/17435889.3.6.859 (2008…
[cited by applicant]
Feldman, E. B. & Carter, A. C. Circulating lipids and lipoproteins in women with metastatic breast carcinoma. The Journal of Clinical Endocrinology & Metabolism 33, 8-13 (1971 ).
[cited by applicant]
Fengming et al.: Biomarkers of inflammatory bowel disease. Dis Markers 2014:710915:1-11 doi:10.1155/2014/710915 (2014).
[cited by applicant]
Ferdosi et al.: Engineered nanoparticles enable deep proteomics studies at scale by leveraging tunable nano-bio interactions. PNAS USA 119(11): e2106053119, pp. 1-11 doi:10.1073/pnas.2106053119 (2022).
[cited by applicant]
Ferdosi et al.: Enhanced Competition at the Nano-Bio Interface Enables Comprehensive Characterization of Protein Corona Dynamics and Deep Coverage of Proteomes. Adv Mater. e2206008, pp. 1-11 doi:10.1002/adma.202206008 (…
[cited by applicant]
Ferdosi et al.: Multi-nanoparticle Workflow Enables Deep Plasma Proteomics at Scale, with Enhanced Precision, and Depths of Coverage. Seer, Inc. (Mar. 2022).
[cited by applicant]
Ferdosi, et al., Proteograph™ multi-nanoparticle proteins coronas enable deep plasma proteomics studies at scale with unmatched sensitivity in combination with trapped ion mobility. Seer, Inc. Mar. 2021. 1 Page.
[cited by applicant]
Ferdosi et al.: The Nanoparticle-Based Plasma Proteomics Workflow enables the Investigation of Glycoproteome. Seer, Inc., Redwood City, CA, poster 1 page (2022).
[cited by applicant]
Ferdosi et al.: The Nanoparticle-Based Plasma Proteomics Workflow enables the Investigation of Glycoproteome. Seer, Inc., Redwood City, CA, poster 1 page (2023).
[cited by applicant]
Ferdosi, et al., Unlocking Plasma Proteomics at Scale: A multi nanoparticle approach to improve the depth of coverage. Seer, Inc. Oct. 2021. 1 Page.
[cited by applicant]
Ferguson, M. K. et al. Sex-associated differences in survival of patients undergoing resection for lung cancer. The Annals of thoracic surgery 69, 245-249 (2000).
[cited by applicant]
Ferrari, M. Cancer nanotechnology: opportunities and challenges. Nature Reviews Cancer 5, 161-171 (2005).
[cited by applicant]
Findeisen et al.: Preanalytical impact of sample handling on proteome profiling experiments with matrix-assisted laser desorption/ionization time-of-flight mass spectrometry. Clin Chem. 51(12):2409-2411 doi:10.1373/clin…
[cited by applicant]
Flory et al.: A Highly Scaled Proteomic Discovery Study for Prostate Cancer Diagnostic Signatures Using ProteographTM Workflow with Trapped Ion Mobility Mass Spectrometry. Oregon Health and Science University, Knight Ca…
[cited by applicant]
Fodor, S.P. et al., Light-directed, spatially addressable parallel chemical synthesis. Science, 251 (4995), 767-773 (1991).
[cited by applicant]
Fontana, R. S. et al. Early Lung Cancer Detection: Results of the Initial (Prevalence) Radiologic and Cytologic Screening in the Mayo Clinic Study 1, 2. American Review of Respiratory Disease 130, 561-565 (1984).
[cited by applicant]
Forbes, et al. COSMIC: exploring the world's knowledge of somatic mutations in human cancer. Nucleic Acids Res. Jan. 2015;43 (Database issue):D805-D811. Epub Oct. 29, 2014.
[cited by applicant]
Foroozandeh et al.: Merging worlds of nanomaterials and biological environment: factors governing protein corona formation on nanoparticles and its biological consequences. Nanoscale Res Lett. 10(221):1-12 doi:10.1186/s…
[cited by applicant]
Fortunato, J. E., Bassiouny, H. S., Song, R.H., et al. Apolipoprotein (a) Fragments in Relation to Human Carotid Plaque Instability. Journal of vascular surgery 2000, 32, 555-563.
[cited by applicant]
Gabizon, A. et al. Cancer nanomedicines: closing the translational gap. The Lancet 384, 2175-2176 (2014).
[cited by applicant]
Gajadhar et al.: An integrated data processing and visualization suite leveraging cloud scalable architecture for large-cohort proteogenomics data analysis and interpretation. Seer, Inc., Redwood City, CA, poster 1 page…
[cited by applicant]
Gajadhar et al.: Unbiased human biofluids analysis using a scalable, deep, automated, multi-nanoparticle-based proteomics workflow. Seer, Inc., Redwood City, CA, poster 1 page (2023).
[cited by applicant]
Gao, W.-M. et al. Distinctive serum protein profiles involving abundant proteins in lung cancer patients based upon antibody microarray analysis. BMC cancer 5, 1 (2005).
[cited by applicant]
Garcia et al.: A high-throughput and robust nanoparticle-based label-free mass spectrometry workflow for deep plasma proteomics at scale. Seer, Inc., Redwood City, CA, poster 1 page (2023).
[cited by applicant]
Gautam, P. et al. Proteins with altered levels in plasma from glioblastoma patients as revealed by iTRAQ-based quantitative proteomic analysis. PloS one 7, e46153 (2012).
[cited by applicant]
Geyer et al.: Revisiting biomarker discovery by plasma proteomics. Mol Syst Biol 13(942):1-15 (2017).
[cited by applicant]
Geyer, P.E., et al., Plasma proteome profiling to assess human health and disease. Cell systems, 2016;2: 185-195.
[cited by applicant]
Ghasemi, F., Hormozi-Nezhad, M. R. & Mahmoudi, M. Identification of catecholamine neurotransmitters using fluorescence sensor array. Analytica Chimica Acta 917, 85-92 (2016).
[cited by applicant]
Ghavami, M. et al. Plasma concentration gradient influences the protein corona decoration on nanoparticles. Rsc Advances 3, 1119-1126 (2013).
[cited by applicant]
Giulio Caracciolo et al: “Disease-specific protein corona sensor arrays may have disease detection capacity”, Nanoscale Horizons, vol. 4, No. 5, Jan. 1, 2019 (Jan. 1, 2019), pp. 1063-1076,XP55681766,ISSN: 2055-6756, DOI…
[cited by applicant]
Go from data to insight with the proteograph analysis suite. Seer.bio. Aug. 2021. Available at: https://seer.bio/resources/document-library/.
[cited by applicant]
Gocheva, V., et al. Quantitative proteomics identify Tenascin-C as a promoter of lung cancer progression and contributor to a signature prognostic of patient survival. Proc Natl Acad Sci U S A 114, E5625-E5634 (2017).
[cited by applicant]
Gopal, K., Grossi, E., Paoletti, P. & Usardi, M. Lipid composition of human intracranial tumors: A biochemical study. Acta neurochirurgica 11, 333-34 7 (1963).
[cited by applicant]
Gossmann, R. et al., Comparative examination of adsorption of serum proteins on HSA- and PLGA-based nanoparticles using SDS-PAGE and LC-MS, European Journal of Pharmaceutics and Biopharmaceutics 2015, 93, 80-87.
[cited by applicant]
Guerrier et al.: A simplified monobuffer multidimensional chromatography for high-throughput proteome fractionation. J Chromatogr A. 1073(1-2):25-33 doi:10.1016/j.chroma.2004.10.002 (2005).
[cited by applicant]
Guo, D. et al. An LXR agonist promotes glioblastoma cell death through inhibition of an EGFR/AKT/SREBP-1/LDLR-dependent pathway. Cancer discovery (2011 ).
[cited by applicant]
Guo, D. et al. EGFR signaling through an Akt-SREBP-1-dependent, rapamycin-resistant pathway sensitizes glioblastomas to anti-lipogenic therapy. Science signaling 2, ra82 (2009).
[cited by applicant]
Guo, D. et al. The AMPK agonist AICAR inhibits the growth of EGFRvlll-expressing glioblastomas by inhibiting lipogenesis. Proceedings of the National Academy of Sciences 106, 12932-12937 (2009).
[cited by applicant]
Guo, Q. et al. Elevated levels of plasma fibrinogen in patients with pancreatic cancer: possible role of a distant metastasis predictor. Pancreas 38, e75-e79 (2009).
[cited by applicant]
Gupta, A. et al. Synergistic antimicrobial therapy using nanoparticles and antibiotics for the treatment of multidrug-resistant bacterial infection. Nano Futures 1, 015004 (2017).
[cited by applicant]
Guturu et al.: High-throughput plasma proteomics to identify diabetes associated protein biomarkers and pQTLs. 1. Seer, Inc., Redwood City, CA; and 2. Weill Cornell Medicine-Qatar, Doha, State of Qatar, poster 1 page (2…
[cited by applicant]
Guturu et al.: Systematic analysis of DIA LC-MS protein rollup strategies and their impact on phenotype association and proteogenomic applications. Seer, Inc., Redwood City, CA; and Massachusetts General Hospital, Bosto…
[cited by applicant]
Hadjidemetriou, et al., A novel scavenging tool for cancer biomarker discovery based on the blood-circulating nanoparticle protein corona. Biomaterials. Jan. 2019; vol. 188: pp. 118-129.
[cited by applicant]
Hadjidemetriou, et al., In Vivo Biomolecule Corona around Blood-Circulating, Clinically Used and Antibody-Targeted Lipid Bilayer Nanoscale Vesicles. ACS Nano, 2015; 9(8): pp. 8142-8156.
[cited by applicant]
Hadjidemetriou, et al., The Human In Vivo Biomolecule Corona onto PEGylated Liposomes: A Proof-of-Concept Clinical Study. Advanced Materials. Nov. 28, 2018:e1803335. doi: 10.1002/adma.201803335. [Epub ahead of print].
[cited by applicant]
Hadjidemetriou, M., Al-Ahmady, Z. & Kostarelos, K. Time-evolution of in vivo protein corona onto blood-circulating PEGylated liposomal doxorubicin (DOXIL) nanoparticles. Nanoscale 8, 6948-6957 (2016).
[cited by applicant]
Hajipour et al., Personalized disease-specific protein corona influences the therapeutic impact of graphene oxide, Nanoscale. 7(19):8978-8994 (2015) (pre-print).
[cited by applicant]
Hajipour, et al., Personalized protein coronas: a “key” factor at the nanobiointerface. Biomate Sci. 2014; 2: 1210-1221.
[cited by applicant]
Hajipour, M. J. et al. Personalized disease-specific protein corona influences the therapeutic impact of graphene oxide. Nanoscale, 2015, 7(19): 8978-8994.
[cited by applicant]
Hajipour, M. J. et al., Sensing of Alzheimer's Disease and Multiple Sclerosis Using Nano-Bio Interfaces, Journal of Alzheimer's Disease 2017, 59, 1187-1202.
[cited by applicant]
Hakimi et al.: Robust and Deep Plasma Proteomics using a Multi Nanoparticle-based Workflow coupled with an Orbitrap Exploris 480 Mass Spectrometry and FAIMS Pro Interface. ThermoFisher Scientific, San Jose, CA; and Seer…
[cited by applicant]
Hanash, S. M., Pitteri, S. J. & Faca, V. M. Mining the plasma proteome for cancer biomarkers. Nature 452, 571-579 (2008).
[cited by applicant]
Hansson, G. K., Hermansson, A. The Immune System in Atherosclerosis. Nature immunology 2011, 12, 204-212.
[cited by applicant]
Hasija, K. & Bagga, H. K. Alterations of serum cholesterol and serum lipoprotein in breast cancer of women. Indian Journal of Clinical Biochemistry 20, 61-66 (2005).
[cited by applicant]
Hassanein, M. et al. The state of molecular biomarkers for the early detection of lung cancer. Cancer prevention research 5, 992-1006 (2012).
[cited by applicant]
Havugimana et al., A census of human soluble protein complexes, Cell, 150(5): 1068-1081, 2012.
[cited by applicant]
Heath, J. R. & Davis, M. E. Nanotechnology and cancer. Annual review of medicine 59, 251 (2008).
[cited by applicant]
Henschke, C. I. et al. Early Lung Cancer Action Project: overall design and findings from baseline screening. The Lancet 354, 99-105 (1999).
[cited by applicant]
Hirsch, F. R., Franklin, W. A., Gazdar, A. F. & Bunn, P. A. Early detection of lung cancer: clinical perspectives of recent advances in biology and radiology. Clinical Cancer Research 7, 5-22 (2001).
[cited by applicant]
Honda, K. et al. Plasma biomarker for detection of early stage pancreatic cancer and risk factors for pancreatic malignancy using antibodies for apolipoprotein-AI I isoforms. Scientific reports 5 (2015).
[cited by applicant]
Hong et al.: Discrimination Analysis of Mass Spectrometry Proteomics for Lung Adenocarcinoma Detection. Laboratory Medicine 42(6):6, pp. 344-349. doi:10.1309/LMXWEJV3FFDR0DHH (2011).
[cited by applicant]
Hornburg, et al., Deep Plasma Proteomics at Scale: A machine learning enhanced multi nanoparticle approach to improve the depth of plasma proteome coverage. Seer, Inc. Nov. 2021. 1 Page.
[cited by applicant]
Hornburg et al.: Enhanced Competition at the Nano-Bio Interface Enables Comprehensive Characterization of Protein Corona Dynamics and Deep Coverage of Proteomes. Seer Inc., Redwood City, CA USA, poster 1 page (2022).
[cited by applicant]
Hornburg, et al., Enhanced competitive protein exchange at the nano-bio interface enables ultra-deep coverage of the human plasma proteome. Seer, Inc. Jan. 2022. pp. 1-18.
[cited by applicant]
Hornburg et al.: Evaluation of an unbiased, deep, and scalable nanoparticle-based proteomics workflow for limited plasma sample vol. from model organisms. Seer, Inc., Redwood City, CA, poster 1 page (2022).
[cited by applicant]
Houerbi et al.: Deep Profiling of the Spaceflight Plasma Proteome reveals Changes in Reactive Oxygen Species, Extracellular Matrix and Lipid Metabolism. Weill Cornell Medicine, New York, NY; Seer, Inc., Redwood City, CA…
[cited by applicant]
Howlader N et al. SEER Cancer Statistics Review, 1975-2014, National Cancer Institute. Bethesda, MD, https://seer. cancer.gov/csr/1975_2014/, based on Nov. 2016 SEER data submission, posted to the SEER web site, Apr. 20…
[cited by applicant]
Huang et al.: Deep, Rapid and Unbiased Plasma Proteomics with Differential Analysis of Proteoforms Enabling Proteogenomic Studies in a NSCLC Lung Cancer Study. Seer, Inc. (Mar. 2022).
[cited by applicant]
Huang et al.: Deep, Rapid and Unbiased Plasma Proteomics with Peptide Correlation Analysis Enabling Proteoform Inference and Differential analysis in a NSCLC Lung Cancer Study. Seer, Inc., Redwood City, CA, poster 1 pag…
[cited by applicant]
Huang et al.: Deep, unbiased and quantitative mass spectrometry-based plasma proteome analyses of adaptive response to COVID-19 vaccine. 1. Seer, Inc., Redwood City, CA, USA; 2. Plexium, San Diego, CA, USA; 3. Federal U…
[cited by applicant]
Huang et al.: Deep, Unbiased and Quantitative mass spectrometry-based plasma proteome analyses of adaptive response to COVID-19 vaccine. Seer, Inc., Redwood City, CA, poster 1 page (2023).
[cited by applicant]
Huang et al.: Proteoform detection in deep plasma proteomics through peptide expression correlation. Seer, Inc., Redwood City, CA, poster 1 page (2023).
[cited by applicant]
Huang, et al. “Superparamagnetic iron oxide nanoparticles conjugated with folic acid for dual target-specific drug delivery and MRI in cancer theranostics” Mater Sci Eng C Mater Biol Appl. Jan. 1, 2017 ;70(Pt1) 763-771.…
[cited by applicant]
Huggins, C., Miller, G. M. & Jensen, E. V. Thermal Coagulation of Serum Proteins II. Deficient Coagulation in Cancer and the lodoacetate Index. Cancer Research 9, 177-182 (1949).
[cited by applicant]
Hughes, Christopher S et al. Single-pot, solid-phase-enhanced sample preparation for proteomics experiments. Nature protocols vol. 14,1 (2019): 68-85. doi:10.1038/s41596-018-0082-x.
[cited by applicant]
Hughes, Christopher S et al. Ultrasensitive proteome analysis using paramagnetic bead technology. Molecular systems biology vol. 10,10 (2014): 757. doi:10.15252/msb.20145625.
[cited by applicant]
Huo et al.: Developing a nanoparticle test for prostate cancer scoring. J Transl Med. 10(44):1-8 doi:10.1186/1479-5876-10-44 (2012).
[cited by applicant]
Huo, Q. et al., A facile nanoparticle immunoassay for cancer biomarker discovery. Journal of Nanobiotechnology 2011, 9, paper 20, 12 pages.
[cited by applicant]
Hwang, T. L., Liang, Y., Chien, K. Y. & Yu, J. S. Overexpression and elevated serum levels of phosphoglycerate kinase 1 in pancreatic ductal adenocarcinoma. Proteomics 6, 2259-2272 (2006).
[cited by applicant]